NASDAQ:ASMB Assembly Biosciences Q4 2025 Earnings Results & Report $20.18 -2.19 (-9.79%) Closing price 04:00 PM EasternExtended Trading$20.87 +0.69 (+3.44%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Assembly Biosciences beat analyst expectations on both earnings and revenue in its Q4 2025 results, released March 19, 2026. The company reported EPS of $2.48 versus the -$0.51 consensus estimate, while revenue of $42.47 million topped the $7.42 million estimate by $35.05 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 19, 2026TimeBefore Market Opens Assembly Biosciences EPS ResultsActual EPS$2.48Consensus EPS -$0.51Beat/MissBeat by +$2.99One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersAssembly Biosciences Revenue ResultsActual Revenue$42.47 millionExpected Revenue$7.42 millionBeat/MissBeat by +$35.05 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Assembly Biosciences Q4 2025 Earnings FAQ Did Assembly Biosciences beat earnings estimates for Q4 2025? Assembly Biosciences (NASDAQ:ASMB) reported earnings of $2.48 per share for Q4 2025, beating the consensus estimate of -$0.51. The report was announced on Thursday, March 19, 2026. What was Assembly Biosciences' revenue for Q4 2025? Assembly Biosciences reported revenue of $42.47 million for Q4 2025, against a consensus estimate of $7.42 million. Assembly Biosciences Earnings HeadlinesAssembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates1 hour ago | globenewswire.comAssembly Biosciences (ASMB) Set to Release Quarterly Earnings on MondayNovember 8, 2026 | americanbankingnews.com$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 12 at 1:00 AM | Profits Run (Ad)Assembly Biosciences (NASDAQ:ASMB) Stock Price Target Cut by UBS GroupNovember 5, 2026 | americanbankingnews.comUBS Adjusts Assembly Biosciences Price Target to $48 From $52, Maintains Buy RatingNovember 3, 2026 | marketscreener.comMAssembly Biosciences, Inc. (NASDAQ:ASMB) Stock Has Consensus Target Price of $47.50November 3, 2026 | americanbankingnews.comSee More Assembly Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Assembly Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Assembly Biosciences and other key companies, straight to your email. Email Address About Assembly BiosciencesAssembly Biosciences (NASDAQ:ASMB) is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus. The company’s pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines. Based in South San Francisco, California, Assembly Biosciences conducts drug research and development with the goal of addressing significant unmet needs in viral disease treatment.View Assembly Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
